380 related articles for article (PubMed ID: 26795291)
1. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
2. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
4. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.
Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D
J Nucl Med; 2015 Jul; 56(7):1075-8. PubMed ID: 25999434
[TBL] [Abstract][Full Text] [Related]
5. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
[No Abstract] [Full Text] [Related]
6. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
7. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
9. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
11. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma.
Luo Y; Li N; Kiesewetter DO; Chen X; Li F
Clin Nucl Med; 2016 Apr; 41(4):341-3. PubMed ID: 26647001
[TBL] [Abstract][Full Text] [Related]
14. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.
Antwi K; Hepprich M; Müller NA; Reubi JC; Fani M; Rottenburger C; Nicolas G; Kaul F; Christ ER; Wild D
Clin Nucl Med; 2020 Sep; 45(9):e386-e392. PubMed ID: 32558709
[TBL] [Abstract][Full Text] [Related]
18. Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [
Tokgöz S; Boss M; Prasad S; Shah P; Laverman P; van Riel M; Gotthardt M
Methods Mol Biol; 2023; 2592():143-153. PubMed ID: 36507990
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
20. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
